Hangzhou Tigermed Consulting
Biotechnology and laboratory services · Hangzhou, Zhejiang
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting, known internationally as Tigermed, is China's leading clinical contract research organization (CRO) and has its global headquarters in the Binjiang District of Hangzhou, Zhejiang Province. Founded in 2004, it is listed in Shenzhen and Hong Kong and reports more than 11,900 employees and over 4,200 customers across 43 countries and regions.
Tigermed provides end-to-end clinical and preclinical development services: development strategy, multi-region clinical trial operations, regulatory affairs, medical writing, data management and biostatistics, pharmacovigilance, central laboratory and central imaging services, real-world studies, and manufacturing and analytical services linked to innovative drug and medical device development. Its network covers more than 140 cities and over 1,100 collaborating clinical research sites in China.
The company supports pharmaceutical and biotechnology companies developing innovative medicines, with more than 210 innovative drug projects supported according to its own figures. Its platform combines a centralized service hub in China with offices and operating presence across Asia-Pacific, Europe, North America, South America and Africa, enabling it to run multi-region trials that meet the regulatory requirements of each market.
Tigermed provides end-to-end clinical and preclinical development services: development strategy, multi-region clinical trial operations, regulatory affairs, medical writing, data management and biostatistics, pharmacovigilance, central laboratory and central imaging services, real-world studies, and manufacturing and analytical services linked to innovative drug and medical device development. Its network covers more than 140 cities and over 1,100 collaborating clinical research sites in China.
The company supports pharmaceutical and biotechnology companies developing innovative medicines, with more than 210 innovative drug projects supported according to its own figures. Its platform combines a centralized service hub in China with offices and operating presence across Asia-Pacific, Europe, North America, South America and Africa, enabling it to run multi-region trials that meet the regulatory requirements of each market.